OncoMatch/Clinical Trials/NCT04242017
Long-term Better Than Short-term ADT With Salvage RT
Is NCT04242017 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Triptoreline for prostate cancer.
Treatment: Triptoreline — A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after radical prostatectomy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Excluded: Stage PN1, M1A-C
All patients have to be pN0. Presence of pN1 disease at original surgical specimen [excluded]. Presence of distant metastasis at time of referral (M1a-c) [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: radical prostatectomy
treated with RP
Must have received: extended pelvic lymph node dissection
treated with ... ePLND
Cannot have received: radiation therapy
Exception: previous RT making new RT impossible (overlapping treatment fields)
Previous RT making new RT impossible (overlapping treatment fields) [excluded].
Cannot have received: androgen deprivation therapy
Active treatment with ADT ... [excluded].
Cannot have received: PSA modulating drugs (finasteride, dutasteride, high-dose corticoids)
Active treatment with ... PSA modulating drugs (finasteride, dutasteride, high-dose corticoids…) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04242017 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, androgen deprivation therapy, PSA modulating drugs disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages